Article

Cancer epigenetics.

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
CA A Cancer Journal for Clinicians (impact factor: 101.78). 10/2010; 60(6):376-92. DOI:10.3322/caac.20085 pp.376-92
Source: PubMed

ABSTRACT Epigenetics refers to stable alterations in gene expression with no underlying modifications in the genetic sequence and is best exemplified by differentiation, in which multiple cell types diverge physiologically despite a common genetic code. Interest in this area of science has grown over the past decades, especially since it was found to play a major role in physiologic phenomena such as embryogenesis, imprinting, and X chromosome inactivation, and in disease states such as cancer. The latter had been previously thought of as a disease with an exclusive genetic etiology. However, recent data have demonstrated that the complexity of human carcinogenesis cannot be accounted for by genetic alterations alone, but also involves epigenetic changes in processes such as DNA methylation, histone modifications, and microRNA expression. In turn, these molecular alterations lead to permanent changes in the expression of genes that regulate the neoplastic phenotype, such as cellular growth and invasiveness. Targeting epigenetic modifiers has been referred to as epigenetic therapy. The success of this approach in hematopoietic malignancies validates the importance of epigenetic alterations in cancer, not only at the therapeutic level but also with regard to prevention, diagnosis, risk stratification, and prognosis.

0 0
 · 
0 Bookmarks
 · 
44 Views

Keywords

cellular growth
 
common genetic code
 
disease states
 
epigenetic alterations
 
epigenetic changes
 
epigenetic therapy
 
exclusive genetic etiology
 
exemplified
 
genetic alterations
 
genetic sequence
 
hematopoietic malignancies validates
 
human carcinogenesis
 
major role
 
microRNA expression
 
molecular alterations lead
 
multiple cell types diverge physiologically
 
physiologic phenomena
 
Targeting epigenetic modifiers
 
therapeutic level
 
X chromosome inactivation
 

Rodolphe Taby